medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (1)


Bile Acids and Portal Hypertension

Arab JP, Barrera F, Arrese M

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 83-86
Archivo PDF: 119.15 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Vorobioff JD, Groszmann RJ. Prevention of portal hypertension: from variceal development to clinical decompensation. Hepatology 2015; 61: 375-81.

  2. Kang SH, Kim MY, Baik SK. Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon. Hepatol Int 2017.

  3. Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology 2015; 61: 1406-15.

  4. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014; 60: 643-53.

  5. Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol 2017; 66: 849-59.

  6. Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs 2016; 21: 167-81.

  7. Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodeling and sinusoidal dysfunction. J Hepatol 2017; 66: 724-33.

  8. Renga B, Cipriani S, Carino A, Simonetti M, Zampella A, Fiorucci S. Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One 2015; 10: e0141082.

  9. Bomzon A, Ljubuncic P. Bile acids as endogenous vasodilators? Biochem Pharmacol 1995; 49: 581-9.

  10. Ljubuncic P, Said O, Ehrlich Y, Meddings JB, Shaffer EA, Bomzon A. On the in vitro vasoactivity of bile acids. Br J Pharmacol 2000; 131: 387-98.

  11. Lautt WW, Daniels TR. Differential effect of taurocholic acid on hepatic arterial resistance vessels and bile flow. Am J Physiol 1983; 244: G366-G369.

  12. Fiorucci S, Zampella A, Cirino G, Bucci M, Distrutti E. Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators. Am J Physiol Heart Circ Physiol 2017; 312: H21-H32.

  13. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55-67.

  14. Khurana S, Raufman JP, Pallone TL. Bile acids regulate cardiovascular function. Clin Transl Sci 2011; 4: 210-8.

  15. Meng Z, Wang Y, Wang L, Jin W, Liu N, Pan H, Liu L, et al. FXR regulates liver repair after CCl4-induced toxic injury. Mol Endocrinol 2010; 24: 886-97.

  16. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013; 368: 17-29.

  17. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 2007; 27: 2606-11.

  18. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006; 103: 3920-5.

  19. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009; 183: 6251-61.

  20. Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int 2017.

  21. Kida T, Tsubosaka Y, Hori M, Ozaki H, Murata T. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33: 1663-9.

  22. Hegade VS, Speight RA, Etherington RE, Jones DE. Novel bile acid therapeutics for the treatment of chronic liver diseases. Therap Adv Gastroenterol 2016; 9: 376-91.

  23. Ali AH, Lindor KD. Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opin Pharmacother 2016; 17: 1809-15.

  24. Flesch D, Cheung SY, Schmidt J, Gabler M, Heitel P, Kramer J, Kaiser A, et al. Nonacidic Farnesoid X Receptor Modulators. J Med Chem 2017; 60: 7199-205.

  25. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59: 2286-98.

  26. Li J, Kuruba R, Wilson A, Gao X, Zhang Y, Li S. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One 2010; 5: e13955.

  27. Mookerjee RP, Yago-Baenas M, Mehta G, Beecher-Jones T, Hooshmand-Rad R, Parihar N, Sharma V, et al. Effect of the FXR agonist obeticholic acid on portal pressure in alcoholic cirrhosis: a phase 2 proof of concept study. Hepatology 2012; 56: 529A.

  28. Klindt C, Deutschmann K, Reich M, Häussinger D, Keitel V. TGR5 plays a protective role against portal hypertension in LCA induced liver damage in mice. J Hepatol 2017; 66: S142.

  29. van Nierop FS, Scheltema MJ, Eggink HM, Pols TW, Sonne DP, Knop FK, Soeters MR. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol 2017; 5: 224-33.




2020     |     www.medigraphic.com